Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing

« Previous Next »Leukemia Research
Volume 30, Issue 2 , Pages 190-203, February 2006

H.B. Koon
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
P. Severy
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
D.S. Hagg
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
K. Butler
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
T. Hill
- Division of Nuclear Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
A.G. Jones
- Division of Nuclear Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
T.A. Waldmann
- Metabolism Branch, National Cancer Institute, National Institutes of Heath, Bethesda, MD, USA
R.P. Junghans
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- Corresponding author. Present address: Department of Surgery, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA. Tel.: +1 401 456 2507; fax: +1 401 456 4812.